The Akt-mTOR Pathway in Down’s Syndrome: The Potential Use of Rapamycin/Rapalogs for Treating Cognitive Deficits

Publisher： Bentham Science Publishers

E-ISSN： 1996-3181|13|1|34-40

ISSN： 1871-5273

Source： CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol.13, Iss.1, 2014-02, pp. : 34-40

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhibitors of mTOR pathway for cancer therapy, moving on from rapalogs to TORKinibs

By  

Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. : 3390-3392

Blackwell Publishing

Access to resources Recommend Favorite

Oxygen-independent Regulation of HIF-1: Novel Involvement of PI3K/ AKT/mTOR Pathway in Cancer

By  

Current Cancer Drug Targets, Vol. 13, Iss. 3, 2013-03 ,pp. : 245-251

Bentham Science Publishers

Access to resources Recommend Favorite

The Quinoline Imidoselenocarbamate EI201 Blocks the AKT/mTOR Pathway and Targets Cancer Stem Cells Leading to a Strong Antitumor Activity

By  

Current Medicinal Chemistry, Vol. 19, Iss. 18, 2012-06 ,pp. : 3031-3043

Bentham Science Publishers

Access to resources Recommend Favorite

mTOR pathway inhibitors in cancer therapy: moving past rapamycin

By Wacheck Volker  

Pharmacogenomics, Vol. 11, Iss. 9, 2010-09 ,pp. : 1189-1191

Future Medicine

Access to resources Recommend Favorite

Homeostasis and the Importance for a Balance Between AKT/mTOR Activity and Intracellular Signaling

By  

Current Medicinal Chemistry, Vol. 19, Iss. 22, 2012-08 ,pp. : 3748-3762

Bentham Science Publishers

Access to resources Recommend Favorite